Table 2.

Anti-FR and anti-allo responses of transduced T cells from patients in cohort 1 and 2 of the study

Cohort 2
Cohort 1, median
Pt. 9Pt. 10Pt. 11Pt. 12Pt. 13Pt. 14Median
Media alone3660344201935153
Melanoma (FR)35542826142728139
IGROV-1 (FR+)1,3752,9608,01012951,3409,0502,1686,501
Allogeneic stimulator PBMCs2,2701,5552,9955625>4,3206032,633
Autologous PBMCs2104563614039298175
OKT35,78413,3179,6202890>3,760>59,0007,7027,457
  • NOTE: T cell reactivity towards the FR tumor antigen and allogeneic stimulator PBMCs was determined by assaying IFN-γ secretion (pg/mL) using ELISA following overnight incubation of T cells with the targets listed. Plastic-coated anti-CD3 (OKT3) was used as an indicator of maximal T cell response. Transduced T cells from all patients were reactive with FR, and T cells from patients in cohort 2 were reactive with allogeneic PBMCs. Nontransduced T cells did not respond against IGROV-1, except for patient 14 in whom 548 pg/mL IFN-γ was secreted (data not shown).